Aroda VR, Erhan U, Jelnes P, et al
FAQ Looking for answers when starting or considering taking a new medicine
We use a very gradual dose-increase schedule specifically designed to help your body adapt and to minimize discomfort
Its standout strength is the rare A+ BBB rating, which provides a level of consumer confidence unmatched in this market segment
A pooled analysis of the STEP 1 through STEP 3 trials, published in Diabetes, Obesity and Metabolism in 2022, examined once-weekly semaglutide 2.4 mg in 2,117 participants against 1,262 on placebo
Mounjaro at 15 mg produces an average weight loss of 22.5% in trials, and Wegovy at 7.2 mg produces 20.7% 8,9